Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation

Abstract Background The bleeding risk among patients with atrial fibrillation is higher early after initiating therapy with vitamin K antagonists (VKAs). Evidence is limited on how prior VKA experience affects bleeding risk when initiating novel oral anticoagulant therapy. We investigated this among...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of medicine 2014-07, Vol.127 (7), p.650-656.e5
Hauptverfasser:	Larsen, Torben Bjerregaard, MD, PhD, Gorst-Rasmussen, Anders, MSc, PhD, Rasmussen, Lars Hvilsted, MD, PhD, Skjøth, Flemming, MSc, PhD, Rosenzweig, Mary, MSc, Lip, Gregory Y.H., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Anticoagulants Anticoagulants - adverse effects Antithrombins - adverse effects Atrial Fibrillation - drug therapy Benzimidazoles - adverse effects beta-Alanine - adverse effects beta-Alanine - analogs & derivatives Bleeding Cardiac arrhythmia Cardiology Clinical outcomes Dabigatran Drug Substitution Female Hemorrhage Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Internal Medicine Male Middle Aged Risk assessment Warfarin Warfarin - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!